title: Sublingual versus vaginal misoprostol for cervical ripening before hysteroscopy: a randomized clinical trial.
abstract: OBJECTIVE
  To evaluate the efficacy of two routes of misoprostol (sublingual and vaginal) for cervical ripening before hysteroscopy.
  
  
  METHODS
  One hundred and ten perimenopausal women who were referred to a tertiary hospital for surgical hysteroscopy enrolled in this double-blind randomized clinical trial. They were divided into two groups to receive 400 mg misoprostol either sublingually or vaginally 6 h before hysteroscopy. The duration of dilatation, Hegar number inserted into the cervix without resistance, and hysteroscopic and drug complications were recorded for all cases.
  
  
  RESULTS
  Forty-nine women in sublingual and 51 in vaginal group participated in the study. Dilatation time was significantly lower in sublingual group (P < 0.001). Median Hegar number passed into the cervix without resistance was 5 in sublingual versus 4 in vaginal group (P = 0.002). Cramp followed by vomiting and diarrhea were the most common side effects of misoprostol in the sublingual group, while cramp followed by vomiting was the most frequent side effect in the vaginal group. Diarrhea was not reported in the vaginal group (P = 0.008).
  
  
  CONCLUSIONS
  Sublingual route of misoprostol could be considered as an effective medication before surgical hysteroscopy in perimenopausal women.
authors.affiliation: Women's Hospital, Tehran University of Medical Sciences, Tehran, Iran. fatedavari@yahoo.com
authors.forename: Fateme Davari
authors.initials: FD
authors.lastname: Tanha
authors.forename: Shohreh
authors.initials: S
authors.lastname: Salimi
authors.forename: Mahsa
authors.initials: M
authors.lastname: Ghajarzadeh
mesh_terms: D000282:Administration, Intravaginal; D000286:Administration, Sublingual; D000328:Adult; D002584:Cervix Uteri / Q000187:drug effects; D004106:Dilatation; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D015907:Hysteroscopy / Q000009:adverse effects / Q000379:methods*; D008875:Middle Aged; D016595:Misoprostol / Q000008:administration & dosage* / Q000009:adverse effects; D010120:Oxytocics / Q000008:administration & dosage* / Q000009:adverse effects; D047648:Perimenopause
chemical_list: D010120:Oxytocics; D016595:Misoprostol